Application of Nanodiagnostics and Nanotherapy to CNS Diseases

Zhang, Weiyuan; Wang, Wenyue; Yu, David Xiang; Xiao, Zhicheng; He, Zhiyong

doi:10.2217/nnm-2018-0163

Cited by 44 publications

(20 citation statements)

References 195 publications

(232 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SPION labeling with near-infrared (NIR) dye, which further improves probe capabilities, reveals deeper tissue penetration due to minimal absorbency of the surface tissue in the spectral region[12]. In vivo fluorescence imaging has undergone remarkable growth with the use of the novel NIR fluorescence (NIRF) probes and optical instruments that allow evaluation of the dynamic migration and distribution of transplanted MSCs as well as the stem cell-based regeneration of tissue[13].…”

Section: Introductionmentioning

confidence: 99%

Triple-modal imaging of stem-cells labeled with multimodal nanoparticles, applied in a stroke model

Silva

Mamani

Nucci

et al. 2019

WJSC

View full text Add to dashboard Cite

BACKGROUND Mesenchymal stem cells (MSCs) have been widely tested for their therapeutic efficacy in the ischemic brain and have been shown to provide several benefits. A major obstacle to the clinical translation of these therapies has been the inability to noninvasively monitor the best route, cell doses, and collateral effects while ensuring the survival and effective biological functioning of the transplanted stem cells. Technological advances in multimodal imaging have allowed in vivo monitoring of the biodistribution and viability of transplanted stem cells due to a combination of imaging technologies associated with multimodal nanoparticles (MNPs) using new labels and covers to achieve low toxicity and longtime residence in cells. AIM To evaluate the sensitivity of triple-modal imaging of stem cells labeled with MNPs and applied in a stroke model. METHODS After the isolation and immunophenotypic characterization of human bone marrow MSCs (hBM-MSCs), our team carried out lentiviral transduction of these cells for the evaluation of bioluminescent images (BLIs) in vitro and in vivo . In addition, MNPs that were previously characterized (regarding hydrodynamic size, zeta potential, and optical properties), and were used to label these cells, analyze cell viability via the 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide assay and BLI analysis, and quantify the internalization process and iron load in different concentrations of MNPs via magnetic resonance imaging (MRI), near-infrared fluorescence (NIRF), and inductively coupled plasma-mass spectrometry (ICP-MS). In in vivo analyses, the same labeled cells were implanted in a sham group and a stroke group at different times and under different MNP concentrations (after 4 h or 6 d of cell implantation) to evaluate the sensitivity of triple-modal images. RESULTS hBM-MSC collection and isolation after immunophenotypic characterization were demonstrated to be adequate in hBM samples. After transduction of these cells with luciferase (hBM-MSC Luc ), we detected a maximum BLI intensity of 2.0 x 10 8 photons/s in samples of 10 6 hBM-MSCs. Analysis of the physicochemical characteristics of the MNPs showed an average hydrodynamic diameter of 38.2 ± 0.5 nm, zeta potential of 29.2 ± 1.9 mV and adequate colloidal stability without agglomeration over 18 h. The signal of iron load internalization in hBM-MSC Luc showed a close relationship with the corresponding MNP-labeling concentrations based on MRI, ICP-MS and NIRF. Under the highest MNP concentration, cellular viability showed a reduction of less than 10% compared to the control. Correlation analysis of the MNP load internalized into hBM-MSC ...

show abstract

Section: Introductionmentioning

confidence: 99%

Triple-modal imaging of stem-cells labeled with multimodal nanoparticles, applied in a stroke model

Silva

Mamani

Nucci

et al. 2019

WJSC

View full text Add to dashboard Cite

show abstract

“…[ 38 ] Furthermore, the methods decrease peripheral toxicity by slowing down the drug release in the brain. [ 39 ] Most of the approaches described above for the passage of the drug across the BBB may be improved by nanotechnology. Some of the nanocarriers used for drug delivery in NDs are discussed below:…”

Section: Nps For Drug Delivery Into the Brain: Role And Advantagesmentioning

confidence: 99%

Recent Advancements of Nanomedicine in Neurodegenerative Disorders Theranostics

Mukherjee

Madamsetty

Bhattacharya

et al. 2020

Adv Funct Materials

107

View full text Add to dashboard Cite

Recent times have witnessed an upsurge in the incidence of neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, Huntington's disease, Prion disease, and amyotrophic lateral sclerosis. The treatment of the same remains a daunting challenge due to the limited access of therapeutic moieties across the blood–brain barrier. Engineered nanoparticles with a size less than 100 nm provide multifunctional abilities for solving these biomedical and pharmacological issues due to their unique physico‐chemical properties along with capability to cross the blood–brain barrier. Needless to mention, there is a scarcity of review articles summarizing recent developments of various nanomaterials including liposomes, polymeric nanoparticles, metal nanoparticles, and bio‐nanoparticles toward the therapeutic and theranostics applications for various neurodegenerative disorders. Here, a broad spectrum of nanomedicinal approaches to eradicate neurodegenerative disorders is provided, along with a brief account of neuroprotection and neuronal tissue regeneration, current clinical status, issues related to safety, toxicity, challenges, and future outlook.

show abstract

“…Whereas early detection is highly involved in the efficient treatment of many brain diseases, such as brain cancer [93] and neurodegenerative disorders [94], the development of novel strategies for neuroimaging is crucial [93]. The interlink between nanotechnology and neuroscience, particularly neuroimaging, has shown a great potential in the field of nanomedicine [95], providing new possibilities for designing contrast agents and nanocarriers that target the brain [96].…”

Section: Nanotechnology-based Approaches For Neuroimagingmentioning

confidence: 99%

“…Moreover, the blood-brain barrier restricts the permeation of conventional contrast agents that are used for neuroimaging as they are usually hydrophobic in nature and have a reduced half-time circulation. Additionally, large hydrophobic molecules can reach the brain parenchyma mostly through active pathways, such as carrier- and receptor-mediated transcytosis or by disrupting the blood-brain barrier which could lead to serious consequences [94,97]. Therefore, nanotechnology strategies mostly involve the development of nanocarriers that can efficiently reach and permeate the blood-brain barrier after oral or intravenous administration.…”

Section: Nanotechnology-based Approaches For Neuroimagingmentioning

confidence: 99%

Contrast Agents Delivery: An Up-to-Date Review of Nanodiagnostics in Neuroimaging

et al. 2019

View full text Add to dashboard Cite

Neuroimaging is a highly important field of neuroscience, with direct implications for the early diagnosis and progression monitoring of brain-associated diseases. Neuroimaging techniques are categorized into structural, functional and molecular neuroimaging, each possessing advantages and disadvantages in terms of resolution, invasiveness, toxicity of contrast agents and costs. Nanotechnology-based approaches for neuroimaging mostly involve the development of nanocarriers for incorporating contrast agents or the use of nanomaterials as imaging agents. Inorganic and organic nanoparticles, liposomes, micelles, nanobodies and quantum dots are some of the most studied candidates for the delivery of contrast agents for neuroimaging. This paper focuses on describing the conventional modalities used for imaging and the applications of nanotechnology for developing novel strategies for neuroimaging. The aim is to highlight the roles of nanocarriers for enhancing and/or overcome the limitations associated with the most commonly utilized neuroimaging modalities. For future directions, several techniques that could benefit from the increased contrast induced by using imaging probes are presented.

show abstract

Application of Nanodiagnostics and Nanotherapy to CNS Diseases

Cited by 44 publications

References 195 publications

Triple-modal imaging of stem-cells labeled with multimodal nanoparticles, applied in a stroke model

Triple-modal imaging of stem-cells labeled with multimodal nanoparticles, applied in a stroke model

Recent Advancements of Nanomedicine in Neurodegenerative Disorders Theranostics

Contrast Agents Delivery: An Up-to-Date Review of Nanodiagnostics in Neuroimaging

Contact Info

Product

Resources

About